Thomas Patrick Kelly

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Waltham, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Nathaniel Adams, Attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Thomas Patrick Kelly

Form 4 holding Chief Financial Officer

Deciphera Pharmaceuticals, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
$0
Report date
11 Jun 2024
Price
$10.58
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Financial Officer

Xenon Pharmaceuticals Inc.

Security class
No securities are beneficially owned.
Shares / value
0
Estimated value
Report date
15 Oct 2025
Price
Ownership
Direct

Insider Reports Filed by Thomas Patrick Kelly

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .